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Portal Vein Thrombosis After Laparoscopic
Splenectomy: An Ongoing Clinical Challenge
Douglas N. Miniati, MD, Arash M. Padidar, MD, Stephen T. Kee, MD,
Thomas M. Krummel, MD, Baird Mallory, MD
ABSTRACT
Objectives: Portal vein thrombosis (PVT) following open
splenectomy is a potentially lethal complication with an
incidence of up to 6%. The objective of this report is to
describe our management of a recent laparoscopic case,
discuss current therapies, and consider antiplatelet ther-
apy for prophylaxis.
Methods: Medical records, laboratory studies, and imag-
ing studies pertaining to a recent case of a laparoscopic
splenectomy were examined. Current literature related to
this topic was reviewed.
Results: A 16-year-old girl underwent laparoscopic sple-
nectomy for idiopathic thrombocytopenic purpura. Her
preoperative platelet count was 96K. She was discharged
on postoperative day 1 after an uneventful operation in-
cluding division of the splenic hilum with an endoscopic
linear stapler. On postoperative day 20, she presented
with a 5-day history of epigastric pain, nausea, and low-
grade fevers without peritoneal signs. Her white blood
cell count was 17.3; her platelets were 476K. Computed
tomography demonstrated thrombosis of the splenic, su-
perior mesenteric, and portal veins propagating into the
liver. Heparinization was begun followed by an unsuc-
cessful attempt at pharmacologic and mechanical throm-
bolysis by interventional radiology. Over the next 5 days,
her pain resolved, she tolerated a full diet, was converted
to oral anticoagulation and sent home. Follow-up radio-
graphic studies demonstrated the development of venous
collaterals and cavernous transformation of the portal
vein.
Discussion: No standard therapy for PVT exists; several
approaches have been described. These include systemic
anticoagulation, systemic or regional medical thromboly-
sis, mechanical thrombolysis, and surgical thrombectomy.
Unanswered questions exist about the most effective
acute therapy, duration of anticoagulation, and the poten-
tial efficacy of routine prophylaxis with perioperative an-
tiplatelet agents. PVT following splenectomy occurs with
both the open and laparoscopic approach.
Key Words: Laparoscopic splenectomy, Portal vein
thrombosis.
INTRODUCTION
Although mesenteric and portal venous thrombosis have
been known clinical entities for over 100 years,1,2 these
processes remain perplexing clinical problems with a
wide spectrum of severity and many possible modes of
therapy. In general, thrombosis of the mesenteric venous
system arises from states of inflammation or infection,
trauma (including elective abdominal surgery), or neo-
plasm, with or without an underlying hypercoagulable
tendency.3,4 Presentation has been described as acute,
subacute, and chronic. Patients with acute and subacute
mesenteric venous thrombosis can present with nonspe-
cific abdominal pain, nausea, anorexia, vomiting, and
diarrhea. Physical examination may reveal normal find-
ings or, in the case of venous infarction, fever, guarding,
and rebound tenderness.4
Portal and mesenteric venous thrombosis after splenec-
tomy has been a well-recognized complication for de-
cades, with a frequency of 7% to 10% documented by
duplex ultrasonography.5,6 Although some authors have
noted that splanchnic venous thrombosis (SVT) is more
common in patients with myeloproliferative disorders,7,8
postsplenectomy SVT has also been noted in patients with
hemolytic anemia, idiopathic thrombocytopenic purpura,
hereditary spherocytosis, and portal hypertension.9–11
Prompt diagnosis is critical and is typically achieved via
color Doppler ultrasonography12 or computed tomogra-
phy.13
METHODS
We present a case of postsplenectomy SVT, describe our
management of this complication, and review the advan-
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CASE REPORT
tages and disadvantages of various treatment modalities
that have been discussed in the literature with emphasis
on the consideration of routine antiplatelet agents for SVT
prophylaxis.
RESULTS
A 16-year-old girl underwent uneventful laparoscopic
splenectomy for idiopathic thrombocytopenic purpura.
Ligation and transection of the splenic hilum was per-
formed with an endoscopic GIA stapler. The blood loss
was less than 20 mL, the procedure lasted 106 minutes,
and she was discharged home on postoperative day 1,
tolerating a regular diet. On postoperative day 20, the
patient called to report a 5-day history of nausea without
emesis, low-grade fevers, and vague, mild abdominal
pain. Her pain was periumbilical and epigastric without
radiation. Her temperature was 37.6°C, pulse 74, blood
pressure 107/50, respiratory rate 20, and the abdominal
examination was significant for mild epigastric tenderness
without guarding or rebound tenderness. Laboratory stud-
ies revealed the following: white blood cell count (WBC),
17 300/mm3; hematocrit, 36.1%; platelets, 47 6000/mm3.
Blood chemistries and liver function tests were within
normal limits. A workup for hypercoagulability states (fac-
tor V Leiden, protein C and S deficiency, prothrombin
20210A mutation, antithrombin III deficiency, and lupus
anticoagulant) yielded normal results. A computed tomog-
raphy (CT) scan of the abdomen and pelvis (Figure 1A)
revealed1 thrombosis involving the portal vein, extending
into the branch veins,2 thrombus of the splenic and supe-
rior mesenteric veins,3 fat stranding and mild edema of the
mesentery, and4 a significant amount of pelvic free fluid.
An abdominal duplex ultrasound examination corrobo-
rated the findings of thrombosed splenic and portal veins
and demonstrated normal flow through the hepatic artery
and veins.
The patient was promptly anticoagulated with a continu-
ous infusion of heparin, maintaining a partial thrombo-
plastin time (PTT) between 60 and 80 seconds. Because of
the extent of thrombosis, her pain, and concern for po-
tential venous mesenteric infarction, on hospital day 2
thrombolysis was attempted by interventional radiology.
A transjugular intrahepatic portosystemic shunt (TIPS)
procedure was attempted, but the portal venous system
could not be cannulated (transjugular or transhepatic
routes) and the procedure was aborted. The patient’s
abdominal examination improved slowly while she was
maintained nil per os (NPO) and on therapeutic heparin.
After instituting oral intake and anticoagulation, the pa-
tient’s abdominal symptoms gradually abated, and she
was discharged on hospital day 10 with normal intestinal
function.
A follow-up computed tomographic scan 2 months
postsplenectomy showed persistent thrombus in the mes-
enteric venous system with early collateralization and cav-
ernous transformation of the porta hepatis (Figure 1B).
After a 6-month period, anticoagulation was terminated.
At that time, a surveillance ultrasound examination dem-
onstrated flow within the portal vein with extensive col-
lateralization around the porta hepatis. To date, the pa-
tient remains clinically stable and asymptomatic.
DISCUSSION
The treatment of patients with postsplenectomy portal
vein or splenic vein thrombosis, or both, includes a wide
Figure 1. (A) Computed tomography (CT) scan on readmission
following laparoscopic splenectomy. Arrow indicates dilated
thrombosed portal venous system. (B) Follow-up CT scan 2
months after readmission, demonstrating cavernous transforma-
tion of the porta hepatis (arrow).
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spectrum between anticoagulation only and emergency
laparotomy. Surgical intervention is infrequently required
but should not be avoided in cases of peritonitis or when
infarcted bowel is suspected. In contrast to arterial intes-
tinal infarction, venous infarction causes an unclear de-
marcation between viable and nonviable bowel, and “sec-
ond-look” laparotomy has been proposed to improve
survival.14 Surgical thrombectomy is warranted only in
select cases of isolated thrombosis of the superior mesen-
teric vein, and portosystemic shunt surgery is both infre-
quently feasible and associated with prohibitively high
morbidity.
Other less invasive modes of therapy have been used
when, as is often the case, no evidence is present of bowel
infarction. In cases of acute mesenteric thrombosis, most
authors agree that prompt intravenous anticoagulation is
warranted.15–17 Early anticoagulation promotes recanaliza-
tion of the portal vein and reduces the risk of splanchnic
venous infarction without increasing the risk of variceal
bleeding.18,19 The probability of recanalization is related to
the extent of thrombosis.19 The most appropriate duration
of this therapy is unknown, but some authors have dem-
onstrated success with oral anticoagulation for 3 months,20
and a general guideline of 6 months to 1 year has also
been suggested.4
Systemic medical thrombolysis with urokinase or recom-
binant tissue plasminogen activator (tPA) has been used,
but carries a higher risk of bleeding complications. Uroki-
nase, a previously effective thrombolytic made from hu-
man sources, has been taken off the market, pending a
recombinant formulation. In recent years, catheter-based,
regional medical thrombolysis has successfully treated
SVT. Local thrombolysis can be achieved via a variety of
techniques. Pharmacologic thrombolytics can be admin-
istered from the arterial circulation (superior mesenteric
artery infusion)21,22 or venous circulation (by the tran-
sjugular or transhepatic route–the latter may carry a higher
risk of bleeding complications). In addition, devices have
been developed to mechanically disrupt and evacuate
thrombus, and several case reports describe various com-
binations of the aforementioned techniques in the treat-
ment of mesenteric thrombosis.23–25 Although these suc-
cess stories exist, some authors question the effectiveness
of catheter-based techniques, citing underlying pylephle-
bitis, extension of thrombus to venular levels, rethrombo-
sis, and inadequate outflow as potential obstacles.26 Cur-
rently, no clear indications for interventional radiology
techniques exist, and therapy should be based on each
patient’s clinical circumstances and the abilities of individ-
ual institutions.
The potential role of antiplatelet agents in the prevention
of SVT has been discussed in the literature. Although
quantitative changes in platelet levels have been shown
not to correlate with the development of postsplenectomy
SVT,27 qualitative changes in platelet function have been
suggested to play a role in thrombotic tendencies.28 One
author8 has instituted treatment with aspirin and low-dose
heparin with good results, but to date, no current standard
of care exists regarding the routine use of antiplatelet
agents in postsplenectomy patients.
CONCLUSION
In summary, PVT following splenectomy occurs with sig-
nificant frequency and should be ruled out in patients
who present with vague abdominal symptoms. The
course of this complication, while potentially devastating,
is usually benign and responds well to anticoagulation
alone. The indications and overall efficacy of catheter-
based thrombolysis remains to be determined, as does the
routine use of postoperative antiplatelet agents or antico-
agulation.
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